See more : Innovative Industrial Properties, Inc. (IIPR-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Ajinomoto Co., Inc. (AJINY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ajinomoto Co., Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Yangzhou Yaxing Motor Coach Co., Ltd. (600213.SS) Income Statement Analysis – Financial Results
- Xiamen Amoytop Biotech Co., Ltd. (688278.SS) Income Statement Analysis – Financial Results
- Prologue S.A. (PROL.PA) Income Statement Analysis – Financial Results
- MetaStat, Inc. (MTST) Income Statement Analysis – Financial Results
- PT. Saraswati Griya Lestari Tbk (HOTL.JK) Income Statement Analysis – Financial Results
Ajinomoto Co., Inc. (AJINY)
About Ajinomoto Co., Inc.
Ajinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. Its Seasonings and Foods segment offers sauces and seasonings products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names; and solutions and ingredients to consumer foods and food service industries. This segment also provides instant noodles under the Knorr Cup Soup, and YumYum names; coffee under the Birdy and Blendy brands; powdered drink under the Birdy 3in1 name; MAXIM products; Chyotto Zeitakuna Kohiten products; and gift sets and office supplies comprising coffee vending machines, tea server, etc. The Frozen Foods segment offers Chinese dumplings, cooked rice, noodles, desserts, shumai, processed chicken, and other products. The Healthcare and Other segment provides amino acids to various industries, such as pharmaceuticals, foods, and cosmetics; sports nutrition products; personal care ingredients; and sterile products, as well as engages in the provision of contract manufacturing services for pharmaceutical intermediates and active ingredients. This segment also offers Ajinomoto Build-up Film, an interlayer insulating material for semiconductor packages. Ajinomoto Co., Inc. was founded in 1909 and is headquartered in Tokyo, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,439.23B | 1,359.12B | 1,149.37B | 1,071.45B | 1,100.04B | 1,127.48B | 1,150.21B | 1,091.20B | 1,185.98B | 1,006.63B | 991.33B | 1,172.44B | 1,197.31B | 1,207.70B | 1,170.88B | 1,190.37B | 1,216.57B | 1,158.51B | 1,106.81B | 1,073.01B | 1,039.55B | 987.73B | 943.54B |
| Cost of Revenue | 927.78B | 888.73B | 723.47B | 665.23B | 696.17B | 731.90B | 752.78B | 704.18B | 768.87B | 659.51B | 635.59B | 788.11B | 793.52B | 804.72B | 785.58B | 833.12B | 856.97B | 828.05B | 795.01B | 760.55B | 743.25B | 717.00B | 680.00B |
| Gross Profit | 511.45B | 470.39B | 425.90B | 406.22B | 403.87B | 395.58B | 397.43B | 387.02B | 417.12B | 347.12B | 355.74B | 384.34B | 403.79B | 402.98B | 385.30B | 357.25B | 359.60B | 330.46B | 311.80B | 312.46B | 296.30B | 270.73B | 263.54B |
| Gross Profit Ratio | 35.54% | 34.61% | 37.05% | 37.91% | 36.71% | 35.09% | 34.55% | 35.47% | 35.17% | 34.48% | 35.88% | 32.78% | 33.72% | 33.37% | 32.91% | 30.01% | 29.56% | 28.52% | 28.17% | 29.12% | 28.50% | 27.41% | 27.93% |
| Research & Development | 28.77B | 25.87B | 24.84B | 25.90B | 27.60B | 27.82B | 27.83B | 27.13B | 24.57B | 32.23B | 31.96B | 32.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 138.10B | 127.02B | 112.28B | 107.85B | 102.52B | 99.49B | 102.40B | 96.12B | 94.28B | 140.32B | 149.58B | 150.46B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.67B | 0.00 |
| Selling & Marketing | 201.63B | 186.49B | 168.85B | 160.65B | 172.08B | 175.12B | 173.86B | 169.45B | 174.44B | 88.32B | 100.37B | 117.80B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 339.73B | 313.51B | 281.12B | 268.50B | 274.60B | 274.60B | 276.26B | 265.57B | 256.84B | 228.64B | 249.95B | 268.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 216.67B | 0.00 |
| Other Expenses | -3.73B | -1.00M | -3.66B | 12.01B | 50.46B | 39.49B | 14.00B | 13.24B | -750.00M | -444.00M | 2.47B | 1.91B | 1.25B | -451.00M | -207.00M | -1.27B | 299.07B | 266.66B | 251.48B | 241.54B | 231.11B | 1.00M | 214.52B |
| Operating Expenses | 364.77B | 325.79B | 302.31B | 306.41B | 352.65B | 341.91B | 318.09B | 305.94B | 326.07B | 272.60B | 293.19B | 313.10B | 331.20B | 333.60B | 321.26B | 316.42B | 299.07B | 266.66B | 251.48B | 241.54B | 231.11B | 216.67B | 214.52B |
| Cost & Expenses | 1,292.55B | 1,214.51B | 1,025.78B | 971.65B | 1,048.82B | 1,073.82B | 1,070.87B | 1,010.11B | 1,094.93B | 932.11B | 928.78B | 1,101.21B | 1,124.73B | 1,138.32B | 1,106.84B | 1,149.54B | 1,156.05B | 1,094.71B | 1,046.48B | 1,002.09B | 974.36B | 933.67B | 894.52B |
| Interest Income | 7.78B | 6.10B | 6.87B | 3.90B | 8.03B | 8.11B | 9.58B | 7.28B | 2.85B | 2.87B | 2.13B | 1.86B | 1.85B | 1.23B | 1.16B | 1.05B | 2.69B | 2.61B | 2.57B | 2.54B | 1.72B | 1.92B | 2.11B |
| Interest Expense | 12.41B | 14.99B | 8.97B | 6.70B | 8.01B | 7.06B | 7.46B | 4.22B | 2.27B | 2.14B | 2.03B | 1.93B | 2.17B | 2.44B | 3.47B | 4.77B | 4.75B | 5.01B | 3.29B | 3.02B | 2.96B | 3.38B | 4.68B |
| Depreciation & Amortization | 78.30B | 71.82B | 66.23B | 63.05B | 61.46B | 52.49B | 51.78B | 46.65B | 51.86B | 45.58B | 47.34B | 44.73B | 48.22B | 54.33B | 60.38B | 60.69B | 55.19B | 45.14B | 40.34B | 39.85B | 39.93B | 38.97B | 37.22B |
| EBITDA | 219.41B | 202.42B | 188.15B | 168.89B | 157.50B | 142.76B | 144.92B | 131.24B | 155.82B | 120.10B | 109.88B | 147.49B | 122.48B | 127.27B | 131.47B | 68.72B | 121.94B | 105.87B | 100.80B | 124.61B | 109.90B | 107.81B | 100.36B |
| EBITDA Ratio | 15.24% | 16.69% | 17.20% | 15.69% | 10.80% | 10.09% | 12.58% | 12.57% | 13.04% | 12.97% | 11.99% | 10.56% | 10.55% | 10.54% | 11.23% | 7.68% | 10.02% | 9.97% | 9.66% | 10.86% | 10.71% | 9.42% | 9.76% |
| Operating Income | 146.68B | 148.93B | 124.57B | 101.12B | 48.77B | 53.15B | 83.32B | 83.62B | 91.05B | 74.52B | 62.55B | 71.23B | 72.58B | 69.37B | 64.03B | 40.83B | 60.52B | 63.80B | 60.32B | 70.92B | 65.19B | 54.06B | 49.02B |
| Operating Income Ratio | 10.19% | 10.96% | 10.84% | 9.44% | 4.43% | 4.71% | 7.24% | 7.66% | 7.68% | 7.40% | 6.31% | 6.08% | 6.06% | 5.74% | 5.47% | 3.43% | 4.97% | 5.51% | 5.45% | 6.61% | 6.27% | 5.47% | 5.19% |
| Total Other Income/Expenses | -4.64B | -8.90B | -2.10B | -2.80B | -52.89B | -38.95B | -7.90B | -7.63B | 639.00M | 4.53B | 11.49B | 29.60B | -493.00M | -20.93B | -19.24B | -37.57B | -8.67B | -8.08B | -3.15B | 10.82B | 1.83B | 11.41B | 9.45B |
| Income Before Tax | 142.04B | 140.03B | 122.47B | 98.32B | 48.80B | 54.20B | 85.45B | 86.68B | 100.32B | 79.05B | 73.30B | 100.83B | 72.09B | 48.44B | 44.79B | 3.26B | 51.85B | 55.72B | 57.17B | 81.74B | 67.02B | 65.47B | 58.46B |
| Income Before Tax Ratio | 9.87% | 10.30% | 10.66% | 9.18% | 4.44% | 4.81% | 7.43% | 7.94% | 8.46% | 7.85% | 7.39% | 8.60% | 6.02% | 4.01% | 3.83% | 0.27% | 4.26% | 4.81% | 5.17% | 7.62% | 6.45% | 6.63% | 6.20% |
| Income Tax Expense | 40.01B | 39.86B | 42.24B | 32.04B | 20.38B | 17.72B | 16.65B | 21.72B | 27.05B | 23.67B | 23.07B | 45.73B | 24.51B | 12.57B | 22.42B | 11.52B | 20.44B | 22.24B | 19.31B | 34.34B | 27.65B | 29.15B | 23.36B |
| Net Income | 87.12B | 94.07B | 75.73B | 59.42B | 18.84B | 29.70B | 60.12B | 53.07B | 71.29B | 46.50B | 42.16B | 48.37B | 41.75B | 30.40B | 16.65B | -10.23B | 28.23B | 30.23B | 34.91B | 44.82B | 36.28B | 33.18B | 31.44B |
| Net Income Ratio | 6.05% | 6.92% | 6.59% | 5.55% | 1.71% | 2.63% | 5.23% | 4.86% | 6.01% | 4.62% | 4.25% | 4.13% | 3.49% | 2.52% | 1.42% | -0.86% | 2.32% | 2.61% | 3.15% | 4.18% | 3.49% | 3.36% | 3.33% |
| EPS | 167.40 | 175.97 | 139.42 | 108.36 | 34.37 | 53.62 | 106.84 | 92.81 | 121.23 | 78.54 | 68.67 | 74.35 | 61.27 | 43.56 | 23.85 | -14.65 | 41.94 | 46.51 | 53.71 | 68.95 | 55.81 | 51.04 | 48.37 |
| EPS Diluted | 167.40 | 175.96 | 139.42 | 108.32 | 34.35 | 53.62 | 106.84 | 92.81 | 121.23 | 78.54 | 68.67 | 74.35 | 61.27 | 43.56 | 23.85 | -14.65 | 41.94 | 46.51 | 53.71 | 68.95 | 55.81 | 51.04 | 48.37 |
| Weighted Avg Shares Out | 520.44M | 534.54M | 543.13M | 548.34M | 548.15M | 553.91M | 568.51M | 571.78M | 588.06M | 591.98M | 613.96M | 650.64M | 681.42M | 697.83M | 697.91M | 698.24M | 673.09M | 649.98M | 649.98M | 649.98M | 649.98M | 649.98M | 649.98M |
| Weighted Avg Shares Out (Dil) | 520.43M | 534.58M | 543.14M | 548.50M | 548.46M | 553.91M | 568.51M | 571.78M | 588.06M | 591.98M | 613.96M | 650.64M | 681.42M | 697.83M | 697.91M | 698.24M | 673.09M | 649.98M | 649.98M | 649.98M | 649.98M | 649.98M | 649.98M |
Ajinomoto Co., Inc. (AJINY) Q2 2024 Earnings Call Transcript
Ajinomoto Co., Inc. (OTCPK:AJINY) Q2 2024 Earnings Conference Call November 7, 2024 4:00 AM ET Company Participants Masataka Kaji - Investor Relations Department Taro Fujie - Representative Executive Officer, President Hiroshi Shirakami - Representative Executive Officer, Executive Vice President Tatsuya...
Ajinomoto Co., Inc. (AJINY) Q1 2024 Earnings Call Transcript
Ajinomoto Co., Inc. (OTCPK:AJINY) Q1 2024 Earnings Conference Call August 5, 2024 4:00 AM ET Company Participants Masataka Kaji - GM Taro Fujie - Director, Representative Executive Officer, President and CEO Eiichi Mizutani - Finance and IR Conference Call Participants...
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
Leveraging Advanced Manufacturing and Strict Quality Control for Superior Performance in Cellular Medicine TOKYO , March 26, 2024 /PRNewswire/ -- Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version...
Essential Japanese Semi Companies For The Reshoring Age
The global COVID-19 pandemic has led to a shift towards reshoring in the semiconductor industry as supply chains are disrupted and geopolitical tensions rise. Reshoring efforts are leading to increased capex spending by semiconductor companies, benefiting equipment suppliers. Japan is...
Ajinomoto: Food, Biotech, And Semis All-In-One
Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer staples segment. Ajinomoto's operational growth catalysts include...
Ajinomoto Co., Inc. to Acquire Forge Biologics for $620 Million1
COLUMBUS, Ohio--(BUSINESS WIRE)--Ajinomoto Co., Inc. ("Ajinomoto Co."; TYO: 2802) and Forge Biologics (Forge), announced today that they have entered into a definitive agreement by which Ajinomoto Co., will acquire Forge, a leading manufacturer of genetic medicines, in an all-cash deal...
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO , Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate...
Source: https://incomestatements.info
Category: Stock Reports